Arcutis Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	313.93	166.54	29.19	3.69	-	-
Other Revenue	4	30	30.42	-	-	-
Revenue	317.93	196.54	59.61	3.69	-	-
Revenue Growth (YoY)	129.21%	229.73%	1517.09%	-	-	-
Cost of Revenue	31.91	19.13	4.99	0.75	-	-
Gross Profit	286.02	177.41	54.62	2.93	-	-
Selling, General & Admin	253.18	229.39	185.15	122.12	60.97	21.34
Research & Development	71.08	76.42	110.58	182.44	145.56	115.31
Operating Expenses	324.26	305.81	295.72	304.56	206.53	136.65
Operating Income	-38.25	-128.4	-241.1	-301.63	-206.53	-136.65
Interest Expense	-14.63	-27.17	-29.71	-15.65	-	-
Interest & Investment Income	9.58	16.17	11.79	5.82	0.17	0.97
Pretax Income	-43.3	-139.39	-259.03	-311.46	-206.36	-135.68
Income Tax Expense	1.02	0.65	3.11	-	-	-
Net Income	-44.32	-140.04	-262.14	-311.46	-206.36	-135.68
Net Income to Common	-44.32	-140.04	-262.14	-311.46	-206.36	-135.68
Shares Outstanding (Basic)	126	121	69	55	49	36
Shares Outstanding (Diluted)	126	121	69	55	49	36
Shares Change (YoY)	11.93%	74.53%	25.94%	11.39%	38.52%	1835.11%
EPS (Basic)	-0.35	-1.16	-3.78	-5.66	-4.18	-3.80
EPS (Diluted)	-0.35	-1.16	-3.78	-5.66	-4.18	-3.80
Free Cash Flow	-33.24	-112.3	-247.49	-258.05	-175.62	-113.35
Free Cash Flow Per Share	-0.26	-0.93	-3.57	-4.69	-3.56	-3.18
Gross Margin	89.96%	90.27%	91.63%	79.54%	-	-
Operating Margin	-12.03%	-65.33%	-404.49%	-8183.04%	-	-
Profit Margin	-13.94%	-71.25%	-439.79%	-8449.76%	-	-
Free Cash Flow Margin	-10.46%	-57.14%	-415.20%	-7000.76%	-	-
EBITDA	-33.19	-125.8	-239.58	-300.69	-206.08	-136.52
EBITDA Margin	-10.44%	-64.01%	-	-	-	-
D&A For EBITDA	5.06	2.6	1.52	0.93	0.45	0.12
EBIT	-38.25	-128.4	-241.1	-301.63	-206.53	-136.65
EBIT Margin	-12.03%	-65.33%	-	-	-	-
Revenue as Reported	317.93	196.54	59.61	3.69	-	-
Advertising Expenses	-	6.9	11.2	1.5	-	-

Updated Oct 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q